Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | Plasma ctDNA as a staging tool in upper tract urothelial carcinoma

Name: Plasma ctDNA as a staging tool in upper tract urothelial carcinoma
Uploaded: 2025-02-13T00:00:00Z
Duration: 2 min 45 s

Roger Li • 13 Feb 2025

GU Cancers 2025

Genitourinary Cancer Urothelial Carcinoma

Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, highlights the challenges in accurately staging upper tract urothelial carcinoma (UTUC) before surgery, due to the limitations of current diagnostic tools. The study explored the use of plasma circulating tumor DNA (ctDNA) to improve staging and prognosis, revealing a higher prevalence in muscle-invasive cases and its potential to predict recurrence and survival outcomes. These findings suggest ctDNA could help tailor treatment strategies for patients with UTUC. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.